Elevation of cerebrospinal fluid protein in patients with diabetes mellitus is associated with duration of diabetes

European Neurology

Volumn 60, Issue 3, 2008, Pages 132-136

  Kobessho, Hiroshi ^a   Oishi, Kenichi ^b   Hamaguchi, Hirotoshi ^b   Kanda, Fumio ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Albumin quotient; Cerebrospinal fluid protein; Diabetes mellitus, duration; Diabetic microvascular complications

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE DURATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGE OF ONSET; AGED; CEREBROSPINAL FLUID PROTEINS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME;

EID: 50449111490     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000144083     Document Type: Article

References (27)

1. Madonick MJ, Margolis J: Protein content of spinal fluid in diabetes mellitus: report on one hundred cases. AMA Arch Neurol Psychiatry 1952;68:641-644.
2. Ives ER: Protein content in the cerebrospinal fluid of diabetic patients. Bull Los Angel Neurol Soc 1957;22:95-111.
3. Kutt H, Hurwitz LJ, Ginsburg SM, McDowell F: Cerebrospinal fluid protein in diabetes mellitus. Arch Neurol 1960;4:31-36.
4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
5. Fishman RA: Cerebrospinal Fluid in Diseases of the Nervous System. Philadelphia, Saunders, 1980, pp 168-325.
6. Eickhoff K, Wikstrom J, Poser S, Bauer H: Protein profile of cerebrospinal fluid in multiple sclerosis with special reference to the function of the blood brain barrier. J Neurol 1977;214:207-215.
7. Schliep G, Felgenhauser K: Serum-CSF protein gradients, the blood-CSF barrier and the local immune response. J Neurol 1978;218:77-96.
8. Felgenhauser K, Schliep G, Rapic N: Evaluation of the blood-CSF barrier by protein gradients and the humoral immune response within the central nervous system. J Neurol Sci 1976;30:113-128.
9. Wiederholt WC, Mulder DW: Cerebrospinal fluid findings in the Landry-Guillain-Barre-Strohl syndrome. Neurology 1965;15:184-187.
10. Gaines JD, Eckman PB, Remington JS: Low CSF glucose level in sarcoidosis involving the central nervous system. Arch Intern Med 1970;125:333-336.
11. Fisher M: An unusual variant of acute idiopathic polyneuritis: syndrome of ophthalmoplegia, ataxia and areflexia. N Engl J Med 1956;255:57-65.
12. Nishimoto Y, Odaka K, Hirata K, Yuki N: Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004;148:200-205.
13. Schliep G, Felgenhauer K: The α2-macroglobulin level in cerebral fluid;a parameter for the condition of the blood-CSF barrier. J Neurol 1974;207:171-181.
14. Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M, Keir G, Lamers K, Link H, Magalhaes A, Massaro AR, Ohman S, Reiber H, Ronnback L, Schluep M, Schuller E, Sindic CJM, Thompson EJ, Trojano M, Wurster U: Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
15. Tourtellotte W: On cerebrospinal fluid immunoglobulin-G (IgG) quotients in multiple sclerosis and other diseases: a review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system. J Neurol Sci 1970;10:279-304.
16. Mogensen CE: Renal function changes in diabetes. Diabetes 1976;25:872-879.
17. Miki E, Kuzuya T, Ide T, Nakao K: Frequency, degree, and progression with time of proteinuria in diabetic patients. Lancet 1972;29:922-924.
18. Krosnick A: Achilles tendon areflexia in diabetic patients: an epidemiological study. JAMA 1964;190:1008-1010.
19. Nielsen NV, Lund FS: Diabetic polyneuropathy: corneal sensitivity, vibratory perception and Achilles tendon reflex in diabetics. Acta Neurol Scand 1979;59:15-22.
20. Gillies MC, Su T, Stayt J, Simpson JM, Naidoo D, Salonikas C: Effect of high glucose on permeability of retinal capillary endothelium in vitro. Invest Ophthalmol Vis Sci 1997;38:635-642.
21. Bendayan M: Vascular permeability in blood capillary. Microsc Res Tech 2002;57:263-268.
22. Raptis AE, Viberti G: Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109(suppl 2):S424-S437.
23. Cunha-Vaz JG, Faria de Abreu JR, Campos AJ, Figo GM: Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 1975;59:649-656.
24. Ohi T, Poduslo JF, Dyck PJ: Increased endoneurial albumin in diabetic polyneuropathy. Neurology 1985;35:1790-1791.
25. Poduslo JF, Curran GL, Dyck PJ: Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc Natl Acad Sci USA 1988;85:4879-4883.
26. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ: Prevalence of diabetic complications in relation to risk factors. Diabetes 1986;35:1322-1339.
27. Krolewski AS, Warram JH: Joslin's Diabetes Mellitus, ed 14. Philadelphia, Lippincott, Williams & Wilkins, 2005, pp 795-808.